Intravenous Mepolizumab for Eosinophilic Esophagitis
The Cincinnati Center for Eosinophilic Disorders at Cincinnati Children's Hospital Medical Center is currently conducting a randomized, double-blind, parallel group clinical trial of intravenous mepolizumab. This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous mepolizumab in pediatric subjects with eosinophilic esophagitis, Aged 2 to 17 Years.
Eligibility
Inclusion criteria:
- 2- 17 years of age
- Isolated eosinophil esophagitis defined as greater than / equal to 20 eosinophils / HPF
Exclusion criteria:
- Current evidence of EGID (Eosinophilic Gastrointestinal Enteropathy) other than eosinophilic esophagitis
- Active H. pylori
- Current or suspected evidence of GERD (Gastroesophageal Reflux Disease) or other causes of esophagitis
- Current evidence or history of celiac disease, esophageal or generalized eosinophilia associated with infiltration in the esophagus (HES, allergic gastroenteritis, bacterial infection, parasitic infestations, collagen vascular disease, vasculitis, allergic drug reaction, graft-versus host disease).
If you are a patient who may be interested in enrolling in this research study or you have further questions, please contact us at 513-803-0153.
Marc E. Rothenberg, MD, PhD
Shane McKee
Shane.McKee@cchmc.org
513-803-0153
